Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1408-1412

  Sekine, Ikuo ^a   Yamada, Kazuhiko ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Kunitoh, Hideo ^a   Ohe, Yuichiro ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; FUROSEMIDE; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; VINDESINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; THORAX CANCER; URINE VOLUME; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUROSEMIDE; HUMANS; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WATER-ELECTROLYTE IMBALANCE;

EID: 34547725778     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00532.x     Document Type: Article

References (24)

1. Johnson SW, O'Dwyer PJ. Cisplatin and its analogues. In: DeVita VT, Hellman S, Roesnberg SA, eds. Cancer: Principles and Practice of Oncology, 7th edn. Philadelphia: Lippincott Williams & Wilkins, 2005; 344-58.
2. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-22.
3. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 3852-9.
4. Gore M. Carboplatin equals cisplatin: But how do I prescribe it? J Clin Oncol 2003; 21: 3183-5.
5. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 1993; 50: 147-58.
6. Walker RJ. Cellular mechanisms of drug nephrotoxicity. In: Seldin DW, Giebisch G, eds. The Kidney, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2000; 2836-60.
7. de Jongh FE, van Veen RN, Veltman SJ et al. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88: 1199-206.
8. Stewart DJ, Dulberg CS, Mikhael NZ et al. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997; 40: 293-308.
9. Taeschner W, Vozeh S. Pharmacokinetic drug data. In: Speight T, Holford N, eds. Avery's Drug Treatment, 4th edn. Auckland: Adis International, 1997; 1629-64.
10. Kleiner SM. Water: An essential but overlooked nutrient. J Am Diet Assoc 1999; 99: 200-6.
11. Hayes DM, Cvitkovic E, Golbey RB et al. High dose cis-platinum diammine dichloride: Amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372-81.
12. Chary KK, Higby DJ, Henderson ES et al. Phase I study of high-dose cis-dichlorodiammineplatinum (II) with forced diuresis. Cancer Treat Rep 1977; 61: 367-70.
13. Al-Sarraf M, Fletcher W, Oishi N et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 1982; 66: 31-5.
14. Ostrow S, Egorin MJ, Hahn D et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity. Cancer Treat Rep 1981; 65: 73-8.
15. Santoso JT, Lucci JA 3rd, Coleman RL et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother Pharmacol 2003; 52: 13-18.
16. Sekine I, Fukuda H, Kunitoh H et al. Cancer chemotherapy in the elderly. Jpn J Clin Oncol 1998; 28: 463-73.
17. Thyss A, Saudes L, Otto J et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12: 2121-5.
18. Lichtman SM, Buchholtz M, Marino J et al. Use of cisplatin for elderly patients. Age Ageing 1992; 21: 202-4.
19. Cubillo A, Cornide M, Lopez JL et al. Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol 2001; 24: 192-7.
20. Hargis JB, Anderson JR, Propert KJ et al. Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 1992; 30: 291-6.
21. de Jongh FE, Verweij J, Loos WJ et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001; 19: 3733-9.
22. Campbell AB, Kalman SM, Jacobs C. Plasma platinum levels: Relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 1983; 67: 169-72.
23. Reece PA, Stafford I, Russell J et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5: 304-9.
24. Nagai N, Kinoshita M, Ogata H et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 1996; 39: 131-7.